Novo Nordisk A/S (NYSE:NVO) Shares Bought by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. grew its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 11.3% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,692,554 shares of the company's stock after buying an additional 576,900 shares during the period. Goldman Sachs Group Inc. owned 0.13% of Novo Nordisk A/S worth $395,291,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of NVO. Revolve Wealth Partners LLC increased its holdings in shares of Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock valued at $214,000 after purchasing an additional 200 shares during the last quarter. Bank of Nova Scotia grew its holdings in Novo Nordisk A/S by 62.5% in the 4th quarter. Bank of Nova Scotia now owns 12,650 shares of the company's stock valued at $1,092,000 after buying an additional 4,866 shares in the last quarter. CenterBook Partners LP increased its stake in shares of Novo Nordisk A/S by 45.9% in the 4th quarter. CenterBook Partners LP now owns 5,557 shares of the company's stock worth $478,000 after acquiring an additional 1,749 shares during the last quarter. Phoenix Financial Ltd. raised its holdings in shares of Novo Nordisk A/S by 37.5% during the 4th quarter. Phoenix Financial Ltd. now owns 19,140 shares of the company's stock worth $1,647,000 after acquiring an additional 5,220 shares during the period. Finally, Scotia Capital Inc. boosted its position in shares of Novo Nordisk A/S by 2.1% during the 4th quarter. Scotia Capital Inc. now owns 285,791 shares of the company's stock valued at $24,586,000 after acquiring an additional 5,833 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Up 7.5%

Novo Nordisk A/S stock opened at $48.76 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74. The firm has a 50 day moving average price of $67.55 and a 200 day moving average price of $71.81. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $139.74. The company has a market capitalization of $217.73 billion, a PE ratio of 13.40, a price-to-earnings-growth ratio of 1.37 and a beta of 0.63.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 84.92% and a net margin of 35.60%. The business had revenue of $11.69 billion during the quarter, compared to analysts' expectations of $77.51 billion. Research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th will be given a dividend of $0.4119 per share. This represents a dividend yield of 240.0%. The ex-dividend date of this dividend is Monday, August 18th. Novo Nordisk A/S's dividend payout ratio is currently 45.05%.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on NVO. HSBC cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price objective for the company. in a research report on Thursday, July 31st. BNP Paribas began coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They set an "underperform" rating for the company. BMO Capital Markets reiterated a "market perform" rating and issued a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Guggenheim lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Finally, UBS Group downgraded Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research report on Tuesday. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of "Hold" and a consensus target price of $93.67.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.